Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Closed
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
NCT#03971474
S1800A is permanently closed to accrual effective November 16, 2020.
